Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison

Table 2

Incidence of serious adverse events, discontinuations due to adverse events, and treatment-emergent adverse events during the double-blind treatment phase.

Safety measure	Double-blind treatment phase			𝑃 value^a
	Pomaglumetad methionil; 𝑁=511	Aripiprazole; 𝑁=161	Total; 𝑁=672
SAEs	42 (8.2)	5 (3.1)	47 (7.0)	0.032*
Discontinuations due to AEs	83 (16.2)	14 (8.7)	97 (14.4)	0.020*
TEAEs	370 (72.4)	109 (67.7)	479 (71.3)	0.272

^∗𝑃<0.05.
^a𝑃 values are from Fisher’s exact test.
AE: adverse event; 𝑁: total number of patients in each treatment group; SAE: serious adverse event; TEAE: treatment-emergent adverse event.